APA
NBIX icon

American Portfolios Advisors’s Neurocrine Biosciences NBIX Stock Holding History

American Portfolios Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$491K Sell
4,619
-96
-2% -$9.74K 0.02% 651
2022
Q2 		$460K Sell
4,715
-182
-4% -$16.8K 0.02% 699
2022
Q1 		$459K Buy
4,897
+2,822
+136% +$239K 0.02% 768
2021
Q4 		$177K Buy
2,075
+148
+8% +$13.6K 0.01% 1219
2021
Q3 		$185K Buy
1,927
+8
+0.4% +$756 0.01% 1148
2021
Q2 		$187K Sell
1,919
-404
-17% -$38.7K 0.01% 1135
2021
Q1 		$226K Buy
2,323
+30
+1% +$3.15K 0.01% 969
2020
Q4 		$220K Buy
2,293
+38
+2% +$3.67K 0.01% 854
2020
Q3 		$217K Buy
2,255
+1,765
+360% +$204K 0.01% 764
2020
Q2 		$59.8K Sell
490
-18
-4% -$1.99K ﹤0.01% 1224
2020
Q1 		$44K Sell
508
-271
-35% -$26.5K ﹤0.01% 1214
2019
Q4 		$83.7K Buy
779
+83
+12% +$8.69K 0.01% 1142
2019
Q3 		$62.7K Sell
696
-43
-6% -$4.02K 0.01% 1186
2019
Q2 		$62.4K Buy
739
+389
+111% +$31.9K 0.01% 1172
2019
Q1 		$30.8K Hold
350
– – ﹤0.01% 1399
2018
Q4 		$25K Hold
350
– – ﹤0.01% 1291
2018
Q3 		$43K Buy
+350
New +$39.7K ﹤0.01% 1179

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

American Portfolios Advisors's NBIX Position: Q3 2022 in Review

American Portfolios Advisors reduced its Neurocrine Biosciences (NBIX) stake by 2% in Q3 2022, selling an estimated $9.74K and leaving 4,619 shares worth $491K. The position accounts for 0.02% of the portfolio, ranked #651.

American Portfolios Advisors first reported a position in NBIX in Q3 2018 and has held it in 17 quarters since. 467 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • American Portfolios Advisors held 4,619 shares of Neurocrine Biosciences worth $491K as of Q3 2022.
  • American Portfolios Advisors sold 96 Neurocrine Biosciences shares in Q3 2022, an estimated $9.74K.
  • Neurocrine Biosciences made up 0.02% of American Portfolios Advisors's portfolio in Q3 2022, its #651 holding.
  • American Portfolios Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 17 quarters since.
  • 467 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.